Marit Sjo Lorentzen

Directeur des opérations chez ARCTICZYMES TECHNOLOGIES ASA

Fortune : 47 550 $ au 30/04/2024

56 ans

Health Technology

Consumer Services

Postes actifs de Marit Sjo Lorentzen

Sociétés	Poste	Début	Fin
ARCTICZYMES TECHNOLOGIES ASA	Directeur des opérations	-	-
ARCTICZYMES TECHNOLOGIES ASA	Directeur/Membre du Conseil	-	-
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Directeur/Membre du Conseil	-	-

University of Tromso

Undergraduate Degree

Internationale

Norvège

Opérationnelle

Sectorielle

Health Technology	3
Consumer Services	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Sociétés cotées	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Entreprise privées	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology

Entreprise privées

Health Technology